USRE44022E1 - Cyclic peptides, method for preparing and use as angiogenesis inhibitors or activators - Google Patents

Cyclic peptides, method for preparing and use as angiogenesis inhibitors or activators Download PDF

Info

Publication number
USRE44022E1
USRE44022E1 US12/418,101 US41810101A USRE44022E US RE44022 E1 USRE44022 E1 US RE44022E1 US 41810101 A US41810101 A US 41810101A US RE44022 E USRE44022 E US RE44022E
Authority
US
United States
Prior art keywords
ile
gln
pro
gly
organic spacer
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related, expires
Application number
US12/418,101
Other languages
English (en)
Inventor
Natacha Betz
Andreas Bikfalvi
Gerard Deleris
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Universite Victor Segalen Bordeaux 2
Universite des Sciences et Tech (Bordeaux 1)
Commissariat a lEnergie Atomique et aux Energies Alternatives CEA
Original Assignee
Universite Victor Segalen Bordeaux 2
Universite des Sciences et Tech (Bordeaux 1)
Commissariat a lEnergie Atomique CEA
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Universite Victor Segalen Bordeaux 2, Universite des Sciences et Tech (Bordeaux 1), Commissariat a lEnergie Atomique CEA filed Critical Universite Victor Segalen Bordeaux 2
Priority to US12/418,101 priority Critical patent/USRE44022E1/en
Application granted granted Critical
Publication of USRE44022E1 publication Critical patent/USRE44022E1/en
Adjusted expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04—Linear peptides containing only normal peptide links
    • C07K7/08—Linear peptides containing only normal peptide links having 12 to 20 amino acids
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/64—Cyclic peptides containing only normal peptide links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Definitions

  • the object of the present invention is novel cyclopeptides and systems comprising them that enable control of angiogenesis.
  • Angiogenesis is a mechanism of neovascularization originating from a pre-existing capillary network. It is particularly important and indispensable in the course of many physiological processes such as embryonic development, implantation of the placenta, but also in different pathologies, in particular in tumor growth, development of metastases, ischemia, vascular diseases of the eye and chronic inflammatory diseases (see Ferrara et al, Nature Medicine, Vol. 5, N o 12, December 1999, pp. 1361-1364 [1] and Hagedorn and Bikfalvi [2]). Angiogenesis is also essential in tissue regeneration and permanent colonization of the biomaterial implants such as bone replacements.
  • Angiogenesis is a multistage process that initially invokes migration, the attachment and adhesion of the endothelial cells and then their proliferation and organization into tubes, in order to form the vascular network necessary to the development of the tissues.
  • VEGF vascular endothelial growth factor
  • VEGF exists in four isoforms: A, B, C and D and of these, isoform A, which comprises 165 amino acids, is a powerful regulator of tumor angiogenesis and appears to be involved in other pathologies such as diabetic retinopathy or chronic inflammatory diseases.
  • VEGF-A is produced by normal or transformed cells. Its expression can be induced by hypoxia, oncogene activation or activation by growth factors such as fibroblast growth factor PGF-2.
  • VEGF-A binds to different receptors, especially the kinase domain receptor KDR (VEGFR-2), which appears to be a very important effector in pathological angiogenesis. Also, inhibition of angiogenesis through the KDR receptor could constitute an interesting therapeutic approach.
  • VEGF-A which comprises 165 amino acids, was described at the end of 1997 and was accessible at the end of June 1998, as disclosed in the document (see Muller Y. A. in Structure, 1997, 5, pp. 1325-1338 [3]).
  • the object of the present invention is specifically novel cyclopeptides having an affinity for binding with the KDR receptor that is higher than that provided by the products mentioned above, which makes possible their utilization in systems activating or inhibiting angiogenesis.
  • a further object of the invention is a cyclopeptide comprising the peptide sequence: -Arg-Ile-Lys-Pro-His-Gln-Gly- (SEQ ID NO: 1)
  • the Arg and Gly residues of the cyclopeptide are connected by a chain that can comprise one or a plurality of organic molecules chosen from the group comprising the natural and synthetic amino acids, or compounds comprising a COOH group and an NH 2 group possibly substituted.
  • the amino acids can be in the L form or in the D form.
  • the synthetic amino acids can be, for example, aromatic and/or heterocyclic compounds comprising a COOH group and an NH 2 group on a structure allowing a spatial conformation close to that of VEGF at the peptide sequence of interest (SEQ I.D. N o : 1) (SEQ ID NO: 1).
  • the aromatic parts can be derivates of benzene, naphthalene, dibenzofurane.
  • the heteroatoms can be atoms of oxygen, nitrogen, silicon, germanium, tin or phosphorous.
  • 4-(2′amino ethyl)-6-dibenzo furan propanoic acid 4-(2′amino ethyl)-6-dibenzofuran propanoic acid can be cited having the formula:
  • silaxanthenes 4-(2′-amino ethyl)-6-(dibenzo furan) propanoic acid
  • the compound when it comprises a substituted NH 2 group it can be of the NHR type wherein R is a hydrocarbon group eventually comprising functional groups of the carboxy, ester, ether, hydroxy and siloxy type.
  • the chain that links the ends of the peptide sequence (SEQ I.D. N o : 1) (SEQ ID NO: 1) described above comprises an amino acid in the D configuration, preferably. D-Phe or D-Tyr.
  • P7 cyclo(Gly-Arg-Ile-Lys-DPro-His- SEQ ID NO: 2 Gln-Gly-Gln-His)
  • P8 cyclo(Gly-Arg-Ile-Lys-Pro-His- SEQ ID NO: 3 Gln-Gly-His)
  • P9 cyclo(Pro-Arg-Ile-Lys-Pro-His- SEQ ID NO: 4 Gln-Gly-Gln-His)
  • P11 cyclo(DPhe-Pro-Gln-Ile-Met-Arg- SEQ ID NO: 5 Ile-Lys-Pro-His-Gln-Gly-Gln-His- Ile-Gly-Glu)
  • P12 cyclo(Gly-Gln-Ile-Met-Arg-Ile- SEQ ID NO: 6 Lys-Pro-His-Gln-Gly-Gln-His-Ile- Gly-Glu)
  • the cyclopeptides of the invention can be used for controlling angiogenesis and treating the diverse pathologies associated with angiogenesis. They can be utilized for these applications in the form of solution or in systems or biomaterials.
  • the cyclopeptides are utilized in the form of a solution, it is generally an aqueous solution that can be administered by oral route or is injectable.
  • the cyclopeptide can be utilized either to assure inhibition of angiogenesis by binding of the cyclopeptide on a VEGF receptor, or for assuring activation of angiogenesis by coupling two cyclopeptides on an organic compound suitable for conferring upon them an efficacious spatial configuration, allowing dimerization of the VEGF receptors.
  • cyclopeptides may be attached if necessary to bioactive agents.
  • a further object of the invention is a composition comprising a cyclopeptide chosen from the following cyclopeptides:
  • P11 cyclo(DPhe-Pro-Gln-Ile-Met-Arg- SEQ ID NO: 5 Ile-Lys-Pro-His-Gln-Gly-Gln-His- Ile-Gly-Glu)
  • P16 cyclo(Arg-Ile-Lys-Pro-His-Gln- SEQ ID NO: 8 Gly)
  • P17 cyclo(Pro-Arg-Ile-Lys-Pro-His- SEQ ID NO: 9 Gln-Gly)
  • P19 cyclo(Gln-Ile-Met-Arg-Ile-Lys- SEQ ID NO: 10 Pro-His-Gln-Gly-Gln-His-Ile-Gly- Glu)
  • P20 cyclo(DPhe-Pro-Gln-Ile-Met-Arg- SEQ ID NO: 11 Ile-Lys-Pro-His-Gln-Gly-Gln-His- Ile-G
  • an object of the invention is a pharmaceutical preparation for activating angiogenesis comprising two identical or different cyclopeptides coupled with a pharmaceutically acceptable organic compound, the cyclopeptides being chosen from the following cyclopeptides:
  • P11 cyclo(DPhe-Pro-Gln-Ile-Met-Arg- SEQ ID NO: 5 Ile-Lys-Pro-His-Gln-Gly-Gln-His- Ile-Gly-Glu)
  • P16 cyclo(Arg-Ile-Lys-Pro-His-Gln- SEQ ID NO: 8 Gly)
  • P17 cyclo(Pro-Arg-Ile-Lys-Pro-His- SEQ ID NO: 9 Gln-Gly)
  • P19 cyclo(Gln-Ile-Met-Arg-Ile-Lys- SEQ ID NO: 10 Pro-His-Gln-Gly-Gln-His-Ile-Gly- Glu)
  • P20 cyclo(DPhe-Pro-Gln-Ile-Met-Arg- SEQ ID NO: 11 Ile-Lys-Pro-His-Gln-Gly-Gln-His- Ile-G
  • the pharmaceutically acceptable organic compound can comprise alternated hydrophilic-hydrophobic sequences and reactive functions with the functions of side chains of amino acids of the cyclopeptide.
  • cyclopeptides When used in the form of systems or biomaterials, the latter also capable of being produced so as to assure either inhibition or activation of angiogenesis.
  • these systems comprise one or a plurality of cyclopeptides, each bonded covalently to one organic spacer arm that can itself be covalently bonded to a support.
  • one sole cyclopeptide affixes to a VEGF receptor and prevents dimerization of the receptor and activation of angiogenesis.
  • these systems can comprise two cyclopeptides bonded covalently to an organic compound in order to dispose the two cyclopeptides in a efficacious spatial configuration for activating angiogenesis.
  • the organic compounds are pharmaceutically acceptable compounds.
  • the They can be formed of alternated hydrophilic-hydrophobic sequences, for example, of the glycol/alkane polyethylene polyethylene glycol/alkane or fluoro alkane type and comprise functions reactive with the amine, hydroxy, carboxylic acid or other functions of the side chains of the cyclopeptide in order to assure its fixation on the compound; they can also comprise acrylic functions.
  • the organic compounds that can be used can also comprise aromatic parts and/or heteroatoms so as to maintain, on the one hand, the two cyclopeptides in an efficacious configuration and to allow, on the other hand, fixation of the two cyclopeptides in this configuration on different supports.
  • the aromatic parts can be derivates of benzene, naphthalene, dibenzofurane.
  • the heteroatoms can be oxygen. nitrogen, silicon, germanium, tin or phosphorous atoms.
  • the distance between the two cyclopeptides fixed on the organic compound is such that, when the system is put in contact with the cells expressing the receptors of the vascular endothelium growth factor VEGF, it allows dimerization of said receptors.
  • the organic compound supporting the two cyclopeptides is generally connected to a support by means of an organic spacer arm.
  • the spacer arm comprises, for example, a hydrocarbon, fluorocarbon, polyether, polyethylene glycol. polyamine, polyamide, polyester, polysiloxane chain or a combination of these, which is functionalized at each end in order to form a covalent bond, on the one hand, with the cyclopeptide and, on the other hand, with the support.
  • the organic spacer arm further comprises a moiety or a peptide sequence capable of being cut by an enzyme system.
  • the enzyme system can be comprised of metalloproteases of the extracellular matrix or other enzymes.
  • the moiety is a peptide sequence that is a substrate of said metalloproteases of the extracellular matrix such as the following peptide sequence, for example: HOOC-Ala-Gly-Leu-Leu-Gly-Gln-Pro-Gly-NH 2 (SEQ ID NO: 26).
  • the spacer arm can comprise in addition bioactive compounds that will also be released to the desired location at the time of cutting the spacer arm.
  • Said bioactive compounds can be cytotoxic agents, anticancer agents or any other active principle, for example, that one would want to use at the level of the KDR receptors.
  • the support on which the cyclopeptide(s) can be affixed can be an organic or inorganic solid.
  • an organic polymer in solid form or in gel form could be used as the support.
  • the polymer utilized is advantageously a biocompatible polymer, biodegradable or nonbiodegradable.
  • the cyclopeptides of the invention can be prepared by methods implementing an automatic synthesis step of a linear peptide on a solid phase by a conventional process, followed by coupling of the ends of the linear peptide either after having released the peptide from the solid phase or by then releasing it from the solid phase.
  • the process comprises:
  • the process comprises:
  • an object of the invention is a method for preparing a system comprising a support on which the cyclopeptide(s) is (are) affixed, which comprises subjecting an organic polymer support to irradiation by ionizing, plasma or photon beams on defined zones of the support and to then grafting onto said zones of the support an organic spacer arm on which the cyclopeptide will be attached.
  • the radiation is done using a mask in order to define the zones to be modified on the support.
  • the ionizing radiation used can be electron beams or accelerated heavy ion beams.
  • the cyclopeptides can be affixed on the organic spacer arms prior to grafting. Their fixation can also be realized after grafting and in this instance, the process further includes a step for fixation of the cyclopeptides on the organic spacer arm after grafting of same.
  • FIG. 1 represents the first embodiment of synthesis of a cyclopeptide according to the invention (schematic representation using the sequence of SEQ ID NO: 2 sequences of SEQ ID NOS: 29, 29, 2 and 2, respectively, in order of appearance);
  • FIG. 2 represents the second embodiment of synthesis of a cyclopeptide according to the invention (schematic representation using the sequence of SEQ ID NO: 10 sequences of SEQ ID NOS: 30, 10 and 10, respectively, in order of appearance);
  • FIG. 3 represents binding of a cyclopeptide according to the invention onto a support by means of an organic spacer arm
  • FIG. 4 represents fixation of an organic compound carrying two cyclopeptides onto a support by means of a spacer arm.
  • VEGF-A vascular endothelium growth factor
  • the peptides P1 to P6, P10, P14, and P15 are linear peptides and peptides P7 to P9, P11, P12, P13 and P16 to P24 are cyclopeptides.
  • Cyclopeptides P7 to P9, P11, P12, P13, P16 to P18 and P23 are prepared using synthesis method A; that is, the first embodiment of the process for synthesizing the cyclopeptides of the invention.
  • Cyclopeptides P12, P13 and P19 to P22 are prepared using the synthesis method B; that is, the second embodiment of the process for synthesizing the cyclopeptides of the invention.
  • Synthesis method A is represented in FIG. 1 which shows the synthesis of cyclopeptide P7.
  • the linear peptide is synthesized on a solid phase P by batch synthesis using the Fmoc/tBu protection technique and an Applied Biosystems 430A automatic synthesizer.
  • pre-charged acid-labile 2-chlorotrityl resins are used, for example the H-His(Trt)-2-ClTrt and H-Ile-2-ClTrt resins or HMPB-BHA resins on a base of BHA polystyrene functionalized using a linker that is Rinker's 4-hydroxymethyl-3-methoxy-phenoxybutanoic acid, for example Fmoc-Gly-HMPB-BHA.
  • the amino acids protected by the 9-fluorenyl methoxy carbonyl (Pmoc) (Fmoc) group are couple coupled using an excess corresponding to four-times the quantity of amino acid activated relative to N-hydroxybenzotriazole (HOBt) ester by means of N,N′-dicyclohexyl cardodiimide carbodiimide (DCC).
  • HOBt N-hydroxybenzotriazole
  • the first line represents the linear peptide, whose side chains re protected either by the trityl groups (Trt) in the case of the amino groups of His and Gly Gln, the Boc (t-butyloxy carbonyl) group in the case of the amino group of Lys and the 2,2,5,7,8-pentamethyl-chromane-6-sulfonyl (Pmc) in the case of Arg.
  • Trt trityl groups
  • Boc t-butyloxy carbonyl
  • Pmc 2,2,5,7,8-pentamethyl-chromane-6-sulfonyl
  • a protected peptide fragment is obtained with a high yield and high degree of purity and negligible loss of the groups protecting the side chains of the amino acids.
  • the protected linear peptides are analyzed by reverse phase high performance liquid chromatography HPLC (Merck RP-18 LiChrosorb column, 7 ⁇ m, 0.4 ⁇ 25 cm) using a linear gradient going from 70 to 100% of B into A, solvent A being an aqueous solution of 0.1% TFA and solvent B being an aqueous solution of FFA TFA 0.1% and 70% acetonitrile.
  • HPLC reverse phase high performance liquid chromatography
  • the protected linear peptide corresponding to P7 is shown in FIG. 1 .
  • it is dissolved in some DCM in order to obtain a final concentration of 1 mg/ml.
  • 6 equivalents of N,N-diisopropyl ethylamine (DIEA) or N-methyl-morpholine (NMM) is added to the solution and cyclization is carried out by means of benzotriazole-1-yl-oxy-tris-pyrrolidino-phosphonium hexafluoro phosphate (PyBOP)/N-hydroxybenzotriazole (HOBt) by using three equivalents of each coupling reagent.
  • the reaction milieu is maintained at 25° C. under nitrogen atmosphere and gentle stirring for 24 to 48 hours until cyclization is complete, which is verified by HPLC.
  • the solvent is eliminated by evaporation under reduced pressure and iced water is added to the residue.
  • the crude precipitate is removed by filtration, washed in fresh water, dried in a desiccator under high vacuum over NaOH and it is used for total deprotection of the side chains without complementary purification.
  • the protected cyclopeptide corresponding to P7 is shown in FIG. 1 .
  • Deprotection side chains of the cyclopeptide is done by means of a 95% TEA solution in the presence of reagents (phenol, thioanisol, triisopropyl silane, water) over 2 to 3 hours. One then evaporates the greater part of the TFA in order to obtain a satisfactory precipitation of the deprotected crude cyclopeptide and 10-times the volume of ice-cooled ether is added. After filtration and washing with fresh ether, the precipitate is dried over NaOH and lyophilized. Then semi-preparative purifications are effected over an Applied Biosystems HPLC column using the LiChrosorb C18 reverse phase column (250 ⁇ 10). Buffers A and B described above are used.
  • FIG. 1 shows the protected cyclopeptide, then the deprotection step culminating in the cyclopeptide P7 of Table 1.
  • the HPLC was done on Merck LiChrosorb RP-18 (7 ⁇ m, 0.4 ⁇ 25 cm) columns and on Interchim LiChrosorb C-18 (5 ⁇ m, 0.4 ⁇ 25 cm) columns by performing elution with a linear gradient of solvent B in solvent A.
  • Solvent A comprises 0.1% TFA in H 2 O.
  • Solvent B comprises 0.1% TFA, 70% acetonitryl acetonitrile and 30% water.
  • a flow of 1 ml/min over a period of 30 minutes was used.
  • UV detection was done at 214 nanometers and 280 nanometers.
  • the purified peptides are characterized by amino acid analysis by performing hydrolysis in HCl 6 M and 2% phenol at 110° C. for 20 to 24 hours and by FAB-MS mass spectrometry.
  • Synthesis method B is shown in FIG. 2 in the case of peptide P19.
  • the P10 linear peptide is synthesized by synthesis on solid phase using the Applied Biosystems 430 A automatic synthesizer, as described in synthesis method A.
  • the first C-terminal amino acid Fmoc-Glu-OAllyl is attached to the NovaSyn TGA 90 ⁇ m (solid phase P) resin by its side chain using a symmetrical anhydride method.
  • the resin is expanded in the N-methylpyrrolidone (NMP) for 30 minutes.
  • NMP N-methylpyrrolidone
  • DIPCDI N,N-diisopropyl carbodiimide
  • Fixation of the carboxylic acid is done by esterification catalyzed by 4-dimethyl amino pyridine (DMAP) at a rate of 0.1 equivalent over 2 hours to give a final substitution of 0.25 mmol/g.
  • the resin charge is estimated by UV quantification of the piperidine-Fmoc addition product at 290 nm.
  • the commercial Fmoc-L-Glu-(PEG-PS)-QAllyl Fmoc-L-Glu-(PEG-PS)-OAllyl (0.18 mmol/g) resin obtained from Perkin Elmer was also used.
  • the resulting amino acids are coupled, protected by the Fmoc group by using an excess corresponding to 4 times the quantity of amino acid activated with respect to HOBt ester by means of DCC.
  • linear peptide with protected side chains is obtained as represented in the first line of FIG. 2 .
  • Allylic deprotection is then performed on the terminal Glu amino acid affixed to the solid phase by treating the resin with the protected peptide by 3 equivalents of [Pd(PPh 3 ) 4 ] in a DCM:AcOH:NMM (37:2:1) under an argon current at 25° C. over a period of 2.5 hours while occasionally gently stirring.
  • the catalyst is removed by washing the resin with 0.5% DIEA in NMP over a period of 2 minutes 3 times in NMP, then in sodium diethyldithiocarbamate 0.5% w/w in NMP and DCM over a period of 2 minutes and repeating 3 times.
  • cyclization of the peptide is done on the solid phase in the following manner.
  • the resin is treated with 20% piperidine in NMP in order to release the N-terminal amino group from the peptide and it is then washed with HOBt 1 N in NMP, then with NMP and DCM.
  • Cyclization is done in solid phase by using 6 equivalents of PyBOP, 6 equivalents of HOBt and 12 equivalents of DIEA in NMP over a period of 4 to 6 hours. Completion of cyclization is verified by the ninhydrine test.
  • the resin is washed several times with MMP and DCM and then dried under high vacuum overnight.
  • the protected cyclopeptide is represented in FIG. 2 .
  • the homogeneous fractions obtained by HPLC are combined by and lyophilized in order to obtain the desired cyclopeptides with a satisfactory degree of purity (greater than 95% by analytical HPLC).
  • linear peptides P1 to P6, P10, P14 and P15 of Table 1 are prepared by conventional peptide synthesis.
  • Table 2 shows the structure and the molecular mass of the P1 to P22 peptides by referencing the peptide sequence of VEGF-A which comprises 165 amino acids.
  • the P1 to P24 peptides are tested as concerns their property of inhibition of the binding of VEGF to its KDR receptor.
  • heparin sulfate deficient Chinese hamster ovarian cells that are transfected with an expression vector containing VEGFR2cDnA (CHOm VEGFR2 cells) are used. It has been shown that the recombinant KDR of the CHO cells have the same characteristics as endothelial cell KDR (see Binétruy-Trournaire et al, EMBO Journal, 19, (7), 2000 pp. 1525-1533 [10]).
  • the CHOm VEGFR2 cells are obtained by transfection of the Chinese hamster ovarian cells that are deficient in heparin sulfate using VEGFR2 cDnA in a psV-7d vector as has been described by Jonca et al in J. Biol. Chem., 1997, 272, pp. 24203 [11].
  • the CHOm VEGFR2 cells are routinely cultured in Dulbecco modified Eagle medium and supplemented with 10% (v/v) fetal calf serum (FCS), 50 U/ml penicillin, 50 ⁇ g/ml streptomycin, 1 mg/ml glucose and 2 mM L-glutamine at 37° C. in a 5% CO 2 atmosphere.
  • FCS fetal calf serum
  • 125 I-Na radiolabeled VEGF is used by utilizing iodine beads (Iodogen).
  • the 125 I-VEGF specific activity is 150,000 to 200,000 cpm/ng.
  • the cells are inoculated into 3.5 cm diameter flasks that have been previously coated with 0.15% gelatin using a density of 200,000 cells per flask and cultured in a complete medium over a period of 2 days.
  • the subconfluent flasks are transferred at 4° C.
  • the cells are washed twice in ice-cooled phosphate buffered saline (PBS) solution and incubated with different concentrations of peptides and 5 ng/mL of 125 I-VEGF in the presence or absence of 50 ng/mL heparin in a binding buffer (DMEM containing 20 mmol/L HEPES, pH 7.4, 0.15% gelatin) over a period of 2 hours at 4° C.
  • DMEM containing 20 mmol/L HEPES, pH 7.4, 0.15% gelatin
  • the cells are washed 3 times using iced PBS and solubized in 1 mL of buffer with 2% Triton X 100, 10% glycol, 1 mg/mL bovine serum albumin BSA.
  • the radioactivity rate bound to the cells is counted in an MR-250 Kontron gamma counter.
  • the non-specific binding is determined by incubation of the cells with 125 I-VEGF and an 200-times excess of unlabeled VEGF. Specific binding is calculated by subtracting non-specific binding from total binding.
  • This assay is performed, preferably on fixed concentrations of the P1 to P22 peptides of 20 ⁇ M, 200 ⁇ M and 400 ⁇ M. All of the linear peptides and some cyclic peptides do not exhibit the inhibitor effect on binding of the VEGF to the KDR at these concentrations. These assays are continued using the cyclopeptides of interest and two linear peptides as controls for an inhibition analysis as a function of dose.
  • cyclopeptides P11, P16, P17, P19, P20, P23 and P24 are very effective in inhibiting binding of VEGF to the KDR receptor.
  • the P22 cyclopeptide that corresponds to the cyclopeptide described in U.S. Pat. No. 5,939,383 [8] is not more effective than the linear peptides P1 to P6, P10, P14 and P15 in inhibiting this binding.
  • the peptides inhibiting binding of the 125 I-VEGF to the VEGFR2 receptor are then tested in in vitro, ex vivo and in vivo angiogenesis assays and relative to their effect on cellular signaling.
  • the results concerning the effect of the active peptides on cellular proliferation, cellular migration and activation of the p42 and p44 kinases (MAP kinases; kinases activated by mitogens) are given here.
  • Cellular proliferation is measured by cell count. 7,000 endothelial cells are placed in the wells of 24-well plates (Costar) in DMEM medium containing newborn bovine serum. After the cells have adhered, the cells are washed in DMEM without serum and incubated with DMEM containing 1% newborn bovine serum, 10 ng/mL of VEGF in the presence or absence of different peptide concentrations. Two days later, the cells area once again stimulated by VEGF in the presence or absence of different concentrations of peptide. At the fifth day. the cells are trypsinized and counted using a Coulter counter. By way of example, the P11 (circular) peptide shows strong inhibition of cellular proliferation. On the other hand, the linear peptide is inactive (Table 3).
  • the flasks are then rinsed and incubated with 10 ng/mL VEGF in the presence or absence of peptide. After 18 hours of incubation a new series of photographs is taken and the before and after stimulation images are superimposed. The cells situated beyond the border of denudation are counted.
  • the P11 (cyclic) peptide in this type of assay strongly inhibits cellular migration.
  • the linear peptide has no effect (Table 3).
  • Phosphorylation of ERK1 (p44) and ERK2 (p42) is measured by Western blot using anti p42/p44 antibodies (New England Biolabs).
  • the capillary endothelial cells are cultivated in DMEM containing 10% newborn bovine serum. Subconfluent cultures are then deprived of serum over a period of 24 hours. The peptides are then added at specific concentrations over 5 minutes to the cells in the presence or absence of 10 ng/mL of VEGF.
  • the cells are then removed from the culture flasks and lysed for 20 minutes over ice in lysis buffer containing 50 nM Hepes, pH 7.4, 75 mM NaCl, 1 mM EDTA, 1% Nonidet P-40 and 0.01% of SDS.
  • the insoluble material is removed by centrifugation and 50 ⁇ g/mL of protein extract are separated by polyacrylamide gel electrophoresis containing sodium dodecyl sulfate (SDS) under denaturing conditions.
  • the proteins are then transferred from the gel onto a nitrocellulose membrane (Amersham Pharmacia Biotech, Orsay) using a transfer apparatus (semi-dry transfer, Bio-Rad, Irvy-surSeine, France).
  • the membrane is then incubated with primary antibodies to p42/p44 then coupled secondaries to peroxidase. Examination is done using the ECLplus system (Amersham Pharmacia Biotech, Orsay). The results are quantified using the Image Quant program (Molecular Dynamics
  • the P11 (cyclic) peptide strongly inhibits phosphorylation of p42/p44.
  • the linear peptide has no effect (Table 3).
  • Table 3 shows the effect of the P11 peptide on cellular proliferation and migration and on phosphorylation of the MAP kinases (p42 and p44). The assays were done as indicated. Inhibition of phosphorylation and migration is indicated in inhibition values at 50% of the biological effect (IC50). 50 ⁇ M of peptides were used for the phosphorylation assays. The degree of phosphorylation is estimated after quantification of the signals obtained using autoradiographic films and the results are expressed in percent inhibition relative to the signal obtained using 10 ng/mL of VEGF alone.
  • the cyclopeptides of the invention can be used for producing angiogenesis inhibitor or activator systems either in soluble form or by coupling them to suitable supports.
  • FIG. 3 shows the first embodiment of an inhibitor system according to the invention.
  • the cyclopeptide is coupled to a suitable support 1 by means of an organic spacer arm 3 which can comprise a moiety 4 capable of being cut by an enzyme system.
  • the organic spacer arm can be comprised of a hydrocarbon, fluorocarbon, polyether, polyethylene glycol, polyamine, polyamide, polyester, polysiloxane chain or a combination of these that is functionalized at each end in order to form a covalent bond on the one hand with the cyclopeptide and on the other hand with the support 1 .
  • the moiety 4 capable of being cut by an enzyme system present in the spacer arm 3 can be particularly a peptide sequence that is a substrate of the enzymes such as the metalloproteases of the extra-cellular matrix.
  • this moiety thus enables releasing the cyclopeptide at the desired location when it is in contact with the appropriate enzymes, thus making it possible for the cyclopeptide to fulfill its function of inhibition of bonding of the VEGF to the KDR receptor and controlling angiogenesis.
  • FIG. 3 shows a singles single cyclopeptide bound to the support.
  • supports can be used that comprise a large number of cyclopeptides, each one bound to the support by an organic spacer arm with or without such a moiety 4 .
  • FIG. 4 shows a further embodiment of the systems of the invention in which two cyclopeptides are used for obtaining an activator effect on the KDR receptors.
  • two cyclopeptides are affixed by a compound 6 which is itself bound to the support 1 by an organic spacer arm 3 ; this arm can also comprise a moiety 4 capable of being cut by an enzyme system.
  • the distance between the two fixed cyclopeptides is such that when the system is brought into contact with cells expressing VEGF receptors, it allows dimerization of said receptors.
  • the organic spacer arm 3 can be of the same type as that of FIG. 3 and comprise a moiety 4 of the same type as that of FIG. 3 .
  • the organic compound 6 can be formed of hydrophilic-hydrophobic alternated sequences of the polyethylene glycol/alkane or fluoroalkane in order to enable appropriate disposition of the two cyclopeptides. Attachment of each cyclopeptide on said compound involves amine or carboxylic acid functions of the side chains of the cyclopeptide or acrylic type functions.
  • the support 1 used in the different embodiments of the systems of the invention can be in solid form or gel form. It can be an organic or inorganic solid.
  • the support is an optionally biocompatible, biodegradable organic peptide.
  • attachment of the organic spacer arm on said polymer can be done by chemical or radiochemical means.
  • the organic polymer support is subjected to irradiation by means of ionizing, plasma or photons beams on defined zones of the support that are intended to receive the spacer arm and the organic spacer arm is then subsequently grafted to those zones either directly or with the aid of a polymerizable monomer by a radical route (radiografting) comprising, for example, amine or carboxylic acid functions.
  • Coupling of the polymer, radiografted or not is done, for example, by creation of amide bonds either between the carboxylic acid functions and the amine functions introduced at the end of the spacer arms or between the amine functions of the support and the carboxylic acid functions introduced at the ends of the spacer arms.
  • the spacer arm is attached to the NH group of this compound, and it corresponds to the formula: CH 2 ⁇ CH—CO—NH—(CH 2 ) 5 —CO—P—CO (Compound 2)
  • P represents the peptide that is a substrate of the metalloprotease of the extra-cellular matrix.
  • the organic compound 1 is prepared in the following steps:
  • the anhydrous THF is mixed with the hexaethylene glycol under nitrogen and while stirring. Then Na is added and allowed to dissolve. The tertiobutyl acrylate is then added. This is turned for 20 hours at room temperature. HCl is added in order to neutralize the solution.
  • the THF is evaporated under reduced pressure, then the solution is flooded with saturated saline solution. The solution is then extracted three times using ethyl acetate. The entire organic phase is again flooded in saturated saline solution. The organic phase is collected and the ethyl acetate evaporated.
  • the pure product (Compound 3) is recovered with a yield of 96%.
  • the pyridine and the starting Compound 3 are placed in a two-necked flask. The entirety is placed at 0° C. under N 2 . Then the TsCl is added. After 15 hours of reaction, the solution is flooded in ice and extracted 3 times using CH 2 Cl 2 . The organic phase is washed with a solution of 2% acetic acid, then with water. The organic phase is then collected, dried over MgSO 4 and evaporated under reduced pressure. The product is purified by passage over a silica column (70/230) with 100% ethyl acetate used as the eluant. The product (Compound 4) is collected with a yield of 65%.
  • the Compound 4 with some DMF is placed in a two-necked flask under N 2 , then NaN 3 is added. It is turned for 20 hours; the solution becomes opaque. The solution is passed over a frit, then the DMF is coevaporated with toluene. A white precipitate is obtained that is diluted with ether. The solution is again passed over the frit and the ether is evaporated.
  • Allylaton is performed by nucleophilic substitution of commercial allyl bromide by the sodium salt of hexaethylene glycol.
  • the derivative obtained is
  • Compound 7 is treated with FmocOSu according to the method used by Chetyrkina et al., Tetrahedron Letters 2000, 41, 1923-1926 [16], for example.
  • Step N o 6 Deprotection of the Tertiobutyloxy Carbonyle Groups.
  • the P23 cyclopeptides are attached to the two functional groups (COOH) of Compound 9 by proceeding in the following manner.
  • the Compound 9 is placed in solution in some THF and then activated by means of N,N-dimethylpropyl, ethyl carbodiimide.
  • the product obtained is identified by infrared spectrometry using Fourier transformation, RMN of the proton and mass spectrometry. It corresponds to the desired product.
  • a spacer arm is attached to the NH group, said spacer aim comprising a polymerizable function.
  • the spacer arm is being prepared by carrying out the following reaction:
  • the salt and the water are placed in a three-necked flask, then the H 2 N (CH 2 ) 5 —COOH amino acid; the entire mixture is cooled to 0° C. While agitating briskly, the acrylic acid chloride is added at a rate of around 3 mL per minute.
  • the yield is 75%.
  • Compound 10 is condensed over the peptide P which is the substrate of the metalloproteases of the extra-cellular matrix at the time of the last step of its synthesis on solid phase, then the entirety is freed from the resin without deprotection of the side chains.
  • the molecule obtained is then condensed using dicyclohexyl carbodiimide over the deprotected Compound 9. Then the side chains of the peptide of the spacer arm are deprotected, then the arm is attached onto the polymer support with the aid of the acrylic functions of the arm.
  • An industrial film made of ethylene polyterephthalate with a 25 ⁇ m thickness is used as the support and it is previously extracted using the Soxhlet using reflux toluene at a temperature of 110° C. over a period of 12 hours, in order to eliminate any trace of organic monomer.
  • a nickel or copper metallic grid having a thickness of approximately 50 ⁇ m is then placed on the polymer film, said grid is pierced with circular holes having a diameter of from 5 to 10 ⁇ m regularly distributed over its entire surface with an interval of approximately 100 ⁇ m.
  • the grid has been manufactured by electroforming in order to have perfect reproducibility and a very high precision of the order of a micrometer.
  • the electron beam has the following characteristics:
  • Irradiation is done in an oxygen-containing atmosphere.
  • the grid is removed from the polymer film and the irradiated polymer film is placed in contact with the organic compound, on which the two cyclopeptides are attached for grafting this compound with the aid of the spacer arm onto the polymer film.
  • This fixation is done by placing the film in contact with a 10 ⁇ 2 M solution of the organic compound previously obtained by working at 40° C.
  • the organic compound is grafted by the acrylic functions of the spacer arm onto the irradiated zones of the polymer film.
  • the final product is characterized by FT-IR and spectrometry and XPS.
  • the organic compound is put into solution in some chloroform and activated using dicyclohexyl carbodiimide DCCl DCCI, then a quantity is added corresponding to 1 molar equivalent of each cyclopeptide and the reaction environment is maintained at 4° C. over a period of 12 hours.
  • the precipitate of dicyclohexylurea is removed by filtration, then the filtrate is evaporated under reduced pressure.
  • the product obtained is characterized by infrared spectrometry using Fourier transformation, proton RMN and mass spectrometry, as previously done.
  • the a spacer arm is attached to the NH group of the organic compound as in Example 1.
  • the assembly is then attached to a support comprised of an 25 ⁇ m thick industrial film made of poly (vinylidene fluoride/hexafluoropropylene) PVDF/HFP.
  • the film is previously subjected to extraction on the Soxhlet in some reflux dichloromethane at a temperature of 40° C. for 12 hours in order to eliminate any trace of organic monomer.
  • the film is then subjected to irradiation under air by accelerated heavy ions.
  • the ions used are oxygen ions haven a primary energy Ep of around 10 MeV/uma at fluences of between 10 7 and 10 9 ions/cm 2 and at intensities of the order of 10 2 to 5 ⁇ 10 2 nA. Operation at low fluence was chosen in such a way that there was no recovery of latent traces.
  • This operation is determined directly by the irradiation parameters (atomic number of the ion, primary energy, fluence).
  • the random distribution of the active centers in the disturbed zone created at the time of irradiation (emergence of latent traces) allows radiografting by means of two organic spacer arms each carrying a cyclopeptide by blocking the distance between the anchoring points in such a way that the distance d between two cyclopeptides favors dimerization of the VEGF receptors.
  • the irradiated zones are used for grafting organic spacer arms carrying the cyclopeptides obtained as described above, by reaction of their acrylic type function with the irradiated support, by virtue of free radicals created along the latent trace of the ion and the emergence of same at the surface of the polymer film.
  • This coupling is done by heating the irradiated film, placed in the presence of a 10 ⁇ 3 M solution of the organic arms carrying the cyclopeptides, to 40° C. in tetrahydrofurane.
  • the final compound is characterized using FT-IR spectrometry and XPS.

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Toxicology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicinal Preparation (AREA)
US12/418,101 2000-10-04 2001-10-02 Cyclic peptides, method for preparing and use as angiogenesis inhibitors or activators Expired - Fee Related USRE44022E1 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
US12/418,101 USRE44022E1 (en) 2000-10-04 2001-10-02 Cyclic peptides, method for preparing and use as angiogenesis inhibitors or activators

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
FR0012654A FR2814744B1 (fr) 2000-10-04 2000-10-04 Cyclopeptides, leur procede de preparation et leur utilisation comme inhibiteur ou activateur de l'angiogenese
FR0012654 2000-10-04
US12/418,101 USRE44022E1 (en) 2000-10-04 2001-10-02 Cyclic peptides, method for preparing and use as angiogenesis inhibitors or activators
US10/381,734 US7199100B2 (en) 2000-10-04 2001-10-02 Cyclic peptides, method for preparing and use as angiogenesis inhibitors or activator
PCT/FR2001/003049 WO2002028895A2 (fr) 2000-10-04 2001-10-02 Cyclopeptides, leur procede de preparation et leur utilisation comme inhibiteur ou activateur de l'angiogenese

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
US10/381,734 Reissue US7199100B2 (en) 2000-10-04 2001-10-02 Cyclic peptides, method for preparing and use as angiogenesis inhibitors or activator

Publications (1)

Publication Number Publication Date
USRE44022E1 true USRE44022E1 (en) 2013-02-19

Family

ID=8854977

Family Applications (2)

Application Number Title Priority Date Filing Date
US12/418,101 Expired - Fee Related USRE44022E1 (en) 2000-10-04 2001-10-02 Cyclic peptides, method for preparing and use as angiogenesis inhibitors or activators
US10/381,734 Ceased US7199100B2 (en) 2000-10-04 2001-10-02 Cyclic peptides, method for preparing and use as angiogenesis inhibitors or activator

Family Applications After (1)

Application Number Title Priority Date Filing Date
US10/381,734 Ceased US7199100B2 (en) 2000-10-04 2001-10-02 Cyclic peptides, method for preparing and use as angiogenesis inhibitors or activator

Country Status (15)

Country Link
US (2) USRE44022E1 (no)
EP (1) EP1328546B1 (no)
JP (1) JP4303958B2 (no)
AT (1) ATE354589T1 (no)
AU (2) AU2001293948B2 (no)
CA (1) CA2424506A1 (no)
DE (1) DE60126802T2 (no)
DK (1) DK1328546T3 (no)
ES (1) ES2282293T3 (no)
FR (1) FR2814744B1 (no)
IL (1) IL155117A0 (no)
NO (1) NO20031377L (no)
NZ (1) NZ525069A (no)
RU (1) RU2249599C2 (no)
WO (1) WO2002028895A2 (no)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8623822B2 (en) * 2002-03-01 2014-01-07 Bracco Suisse Sa KDR and VEGF/KDR binding peptides and their use in diagnosis and therapy
AU2003278807A1 (en) * 2002-03-01 2004-08-13 Bracco International B.V. Kdr and vegf/kdr binding peptides and their use in diagnosis and therapy
US7211240B2 (en) * 2002-03-01 2007-05-01 Bracco International B.V. Multivalent constructs for therapeutic and diagnostic applications
US7261876B2 (en) 2002-03-01 2007-08-28 Bracco International Bv Multivalent constructs for therapeutic and diagnostic applications
US7794693B2 (en) * 2002-03-01 2010-09-14 Bracco International B.V. Targeting vector-phospholipid conjugates
HUE039154T2 (hu) * 2003-03-03 2018-12-28 Dyax Corp HGF receptort (cMet) specifikusan kötõ peptidek és alkalmazásaik
ES2340885T3 (es) * 2006-01-17 2010-06-10 N.V. Organon Hidrolisis enzimatica selectiva de esteres terc-butilicos c terminal de peptidos.
EP2106404A2 (en) 2006-10-19 2009-10-07 Ramot at Tel Aviv University Ltd. Compositions and methods for inducing angiogenesis
EP2456784B1 (en) 2009-07-24 2017-01-11 Advanced Accelerator Applications S.A. Compounds modulators of vegf activity and uses thereof
FR2969999B1 (fr) 2011-01-03 2013-02-08 Commissariat Energie Atomique Conjugue, son procede de preparation et ses utilisations
EP2894161B1 (en) * 2012-09-03 2019-12-25 The University of Tokyo Peptide for inhibiting vascular endothelial growth factor receptor
CN103724290B (zh) * 2013-11-15 2015-04-29 浙江大学 一种环肽化合物clavatustide A及其产生菌、制备方法和应用

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0844252A2 (en) 1996-11-15 1998-05-27 Remacle, José Cyclic peptides bearing a tail designed for subsequent chemical coupling and process for preparing same
US5849692A (en) 1993-04-01 1998-12-15 Merck Patent Gesellschaft Mit Beschrankter Haftung Cyclic peptides containing Arg-Gly-Asp, and derivatives thereof, as adhesion inhibitors
WO1999040947A2 (en) 1998-02-11 1999-08-19 Resolution Pharmaceuticals Inc. Angiogenesis targeting molecules
WO2000053219A2 (en) 1999-03-11 2000-09-14 Entremed, Inc. Compositions and methods for treating cancer and hyperproliferative disorders

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5849692A (en) 1993-04-01 1998-12-15 Merck Patent Gesellschaft Mit Beschrankter Haftung Cyclic peptides containing Arg-Gly-Asp, and derivatives thereof, as adhesion inhibitors
EP0844252A2 (en) 1996-11-15 1998-05-27 Remacle, José Cyclic peptides bearing a tail designed for subsequent chemical coupling and process for preparing same
US5939383A (en) * 1996-11-15 1999-08-17 Remacle; Jose Cyclic peptides bearing a tail designed for subsequent chemical coupling and process for preparing same
WO1999040947A2 (en) 1998-02-11 1999-08-19 Resolution Pharmaceuticals Inc. Angiogenesis targeting molecules
WO2000053219A2 (en) 1999-03-11 2000-09-14 Entremed, Inc. Compositions and methods for treating cancer and hyperproliferative disorders

Non-Patent Citations (21)

* Cited by examiner, † Cited by third party
Title
B. Ivanov et al.: "Synthesis and use of a new bromoacetyl-derivatized heterotrifunctional amino acid for conjugation of cyclic RGD-containing peptides derived from human bone sialoprotein" Bioconjugate Chemistry, vol. 6, pp. 269-277, 1995.
Bertrand Carboni et al.: "Aliphatic amino azides as key building blocks for efficient polyamine syntheses" J. Org. Chem., vol. 58, pp. 3736-3741 1993.
Christine Piossek et al.: "Vascular endothelial growth factor (VEGF) receptor II-derived peptides inhibit VEGF" The Journal of Biological Chemistry, vol. 274, No. 9, pp. 5612-5619 1999.
D. Delforge et al.: "Solid-phase synthesis of tailed cyclic peptides: the use of alpha-allyl-protected aspartic acid leads to aspartimide and tetramethylguanidium formation" Letter In Peptide Science, vol. 3, pp. 89-97, May 1, 1996.
D. Scott Wilbur et al.: "Biotin reagents for antibody pretargeting, 3. Synthesis, radioiodination, and evaluation of biotinylated starburst dendrimers" Bioconjugate Chem., vol. 9, pp. 813-825, 1998.
Frederic Jonca et al.: "Cell release of bioactive fibroblast growth factor 2 by exon 6-encoded sequence of vascular endothelial growth factor" The Journal of Biological Chemistry, vol. 272, No. 39, pp. 24203-24209, 1997.
Haimanot Bekele et al.: "Improved synthesis of the Boc and Fmoc derivatives of 4-(4'-aminoethyl)-6-dibenzofuranpropionic acid: an unnatural amino acid that nucleates beta-sheet folding" J. Org. Chem., vol. 62, pp. 2259-2262, 1997.
Haimanot Bekele et al.: "Improved synthesis of the Boc and Fmoc derivatives of 4-(4′-aminoethyl)-6-dibenzofuranpropionic acid: an unnatural amino acid that nucleates beta-sheet folding" J. Org. Chem., vol. 62, pp. 2259-2262, 1997.
Katherine D. McReynolds et al.: "Syntehsis of biotinylated glycoconjugates and their use in a novel ELISA for direct comparison of HIV-1 Gp120 recognition of GalCer and related carbohydrate analogues" Bioconjugate Chem., vol. 10, pp. 1021-1031, 1999.
LG Presta et al.: "Humanization of an anti-vascular endothelial growth factor monoclonal antibody for the therapy of solid tumors and other disorders" Cancer Res., vol. 57, No. 20, pp. 4593-4599, Oct. 1997.
Martin Hagedorn et al.: "Target molecules for anti-angiogenic therapy: from basic research to clinical trials" Critical Reviews in Oncology/Hematology, vol. 34, pp. 89-110, 2000.
N. Ortega et al.: "Systemic activation of the vascular endothelial growth factor receptor KDR/flk-1 selectivity triggers endothelial cells with an angiogenic phenotype" Am J Panthol. vol. 151, No. 5, pp. 1215-1224, Nov. 1997.
Napoleone Ferrara et al.: "Clinical applications of angiogenic growth factors and their inhibitors" Nature Medicine, vol. 5, No. 12, pp. 1359-1364, Dec. 1999.
Oliver Seltz et al.: "HYCRON, an allylic anchor for high-efficiency solid phase synthesis of protected peptides and glycopeptides" J. Org. Chem., vol. 62, pp. 813-826, 1997.
Roselyne Binetruy-Tournaire et al.: "Identification of a peptide blocking vascular endothelial growth factor (VEGF)-mediated angiogenesis" The EMBO Journal, vol. 19, No. 7, pp. 1525-1533, 2000.
S.A. Kates et al.: "Automated allyl cleavage for continuous-flow synthesis of cyclic and branched peptides" Analytical Biochemistry, vol. 212, pp. 303-310 1993.
Svitlana Chetyrkina et al.: "Synthesis of N-Fmoc-4-[(diethylphosphone)-2', 2'-difluoro-1'-hydroxyethyl]phenylalanine, a novel phosphotyrosyl mimic for the preparation of signal transduction inhibitory peptides" Tetrahedron Letters vol. 41, pp. 1923-1926, 2000.
Svitlana Chetyrkina et al.: "Synthesis of N-Fmoc-4-[(diethylphosphone)-2′, 2′-difluoro-1′-hydroxyethyl]phenylalanine, a novel phosphotyrosyl mimic for the preparation of signal transduction inhibitory peptides" Tetrahedron Letters vol. 41, pp. 1923-1926, 2000.
Wayne J. Fairbrother et al.: "Novel peptides selected to bind vascular endothelial growth factor target the receptor-binding site" Biochemistry, vol. 37, pp. 17754-17764, 1998.
Yasufumi Sato et al.: "Autocrine activities of basic fibroblast growth factor: regulation of endothelial cell movement plasminogen activator synthesis, and DNA synthesis" The Journal of Cell Biology, vol. 107, pp. 1199-1205, Sep. 1988.
Yves A. Muller et al.: "The crystal structure of vascular endothelial growth factor (VEGF) refined to 1.93 A resolution: multiple copy flexibility and receptor binding" Structure, vol. 5, No. 10, pp. 1325-1338, Oct. 15, 1997.

Also Published As

Publication number Publication date
RU2249599C2 (ru) 2005-04-10
JP4303958B2 (ja) 2009-07-29
ATE354589T1 (de) 2007-03-15
NO20031377L (no) 2003-05-02
EP1328546B1 (fr) 2007-02-21
US20040092434A1 (en) 2004-05-13
DE60126802T2 (de) 2007-11-08
AU9394801A (en) 2002-04-15
JP2004510784A (ja) 2004-04-08
ES2282293T3 (es) 2007-10-16
IL155117A0 (en) 2003-10-31
DK1328546T3 (da) 2007-06-04
US7199100B2 (en) 2007-04-03
NO20031377D0 (no) 2003-03-26
CA2424506A1 (en) 2002-04-11
DE60126802D1 (de) 2007-04-05
WO2002028895A3 (fr) 2002-06-06
WO2002028895A2 (fr) 2002-04-11
EP1328546A2 (fr) 2003-07-23
FR2814744B1 (fr) 2002-11-29
AU2001293948B2 (en) 2005-11-03
NZ525069A (en) 2004-09-24
FR2814744A1 (fr) 2002-04-05

Similar Documents

Publication Publication Date Title
USRE44022E1 (en) Cyclic peptides, method for preparing and use as angiogenesis inhibitors or activators
US5965695A (en) Modified peptide and peptide libraries with protease resistance, derivatives thereof and methods of producing and screening such
JP2594259B2 (ja) 膜アンカー／活性化合物接合体およびその製法
JP2005272480A (ja) トロンボスポンジン−様活性を有するペプチド及びその治療のための使用
Zhang et al. Kilogram-scale synthesis of osteogenic growth peptide (10–14) using a fragment coupling approach
NO844123L (no) Fremgangsmaate for fremstilling av nonapeptider og dodekopeptider
FI67368C (fi) Foerfarande foer framstaellning av nya terapeutiskt anvaendbara polypeptider
CN112028982A (zh) 一种靶向pd-l1的共价多肽抑制剂及其制备方法和应用
JP4568842B2 (ja) 熱帯熱マラリア原虫のエノラーゼ蛋白質の部分ペプチドの製造方法
Langer et al. A bicyclic cispentacin derivative as a novel reverse turn inducer in a GnRH mimetic
WO2021250662A1 (en) Ubiquitin high affinity peptides, and methods of using same, and identifying same
EP2108698A1 (en) Vascular endothelial cell-binding peptide
JP2620727B2 (ja) ペプチド脂質
CN113164613B (zh) 二聚的肽-磷脂缀合物的优化方法
EP1370587A2 (en) Antiangiogenic peptides derived from endostatin
DE19845434C1 (de) Gewebebindende Peptide, ihre Identifizierung, Herstellung und Verwendung
Ma et al. Chemical Synthesis of Peptides and Proteins Bearing Base‐Labile Post‐Translational Modifications: Evolution of the Methods in Four Decades
JP2005306762A (ja) 細胞死誘導のためのペプチド
JPS62174098A (ja) マイトジエン活性を有するペプチド
CN113164613A (zh) 二聚的肽-磷脂缀合物的优化方法
JPH0578391A (ja) ペプチドおよびその塩
Anderson Extracellular matrix biomimicry for the endothelialization of cardiovascular materials
JPH04198194A (ja) ポリペプチドおよびその用途
JPH0570483A (ja) ペプチドおよびその塩
JPH0570492A (ja) ペプチドおよびその塩

Legal Events

Date Code Title Description
FPAY Fee payment

Year of fee payment: 8

FEPP Fee payment procedure

Free format text: MAINTENANCE FEE REMINDER MAILED (ORIGINAL EVENT CODE: REM.); ENTITY STATUS OF PATENT OWNER: LARGE ENTITY

LAPS Lapse for failure to pay maintenance fees

Free format text: PATENT EXPIRED FOR FAILURE TO PAY MAINTENANCE FEES (ORIGINAL EVENT CODE: EXP.); ENTITY STATUS OF PATENT OWNER: LARGE ENTITY